T cell profiling reveals high CD4(+)CTLA-4(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

S.J.A.M. Santegoets, A.G.M. Stam, S.M. Lougheed, H. Gall, P.E.T. Scholten, M. Reijm, K. Jooss, N. Sacks, K. Hege, I. Lowy, J.M. Cuillerot, B.M.E. von Blomberg, R.J. Scheper, A.J.M. van den Eertwegh, W.R. Gerritsen, T.D. de Gruijl

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)245-256
JournalCancer Immunology and Immunotherapy
Volume62
Issue number2
DOIs
Publication statusPublished - 2013

Cite this

Santegoets, S.J.A.M. ; Stam, A.G.M. ; Lougheed, S.M. ; Gall, H. ; Scholten, P.E.T. ; Reijm, M. ; Jooss, K. ; Sacks, N. ; Hege, K. ; Lowy, I. ; Cuillerot, J.M. ; von Blomberg, B.M.E. ; Scheper, R.J. ; van den Eertwegh, A.J.M. ; Gerritsen, W.R. ; de Gruijl, T.D. / T cell profiling reveals high CD4(+)CTLA-4(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. In: Cancer Immunology and Immunotherapy. 2013 ; Vol. 62, No. 2. pp. 245-256.
@article{4a88503e74724ef2b258ad467a3161bf,
title = "T cell profiling reveals high CD4(+)CTLA-4(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment",
author = "S.J.A.M. Santegoets and A.G.M. Stam and S.M. Lougheed and H. Gall and P.E.T. Scholten and M. Reijm and K. Jooss and N. Sacks and K. Hege and I. Lowy and J.M. Cuillerot and {von Blomberg}, B.M.E. and R.J. Scheper and {van den Eertwegh}, A.J.M. and W.R. Gerritsen and {de Gruijl}, T.D.",
year = "2013",
doi = "10.1007/s00262-012-1330-5",
language = "Undefined/Unknown",
volume = "62",
pages = "245--256",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

T cell profiling reveals high CD4(+)CTLA-4(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. / Santegoets, S.J.A.M.; Stam, A.G.M.; Lougheed, S.M.; Gall, H.; Scholten, P.E.T.; Reijm, M.; Jooss, K.; Sacks, N.; Hege, K.; Lowy, I.; Cuillerot, J.M.; von Blomberg, B.M.E.; Scheper, R.J.; van den Eertwegh, A.J.M.; Gerritsen, W.R.; de Gruijl, T.D.

In: Cancer Immunology and Immunotherapy, Vol. 62, No. 2, 2013, p. 245-256.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - T cell profiling reveals high CD4(+)CTLA-4(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

AU - Santegoets, S.J.A.M.

AU - Stam, A.G.M.

AU - Lougheed, S.M.

AU - Gall, H.

AU - Scholten, P.E.T.

AU - Reijm, M.

AU - Jooss, K.

AU - Sacks, N.

AU - Hege, K.

AU - Lowy, I.

AU - Cuillerot, J.M.

AU - von Blomberg, B.M.E.

AU - Scheper, R.J.

AU - van den Eertwegh, A.J.M.

AU - Gerritsen, W.R.

AU - de Gruijl, T.D.

PY - 2013

Y1 - 2013

U2 - 10.1007/s00262-012-1330-5

DO - 10.1007/s00262-012-1330-5

M3 - Article

VL - 62

SP - 245

EP - 256

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -